Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

University of Tennessee Medical Center at Knoxville, Knoxville, TN

2 abstracts

Abstract
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).
Org: University Hospital Essen, Essen, Germany, University Hospital Zurich, Zurich, Switzerland, Gustave Roussy, Villejuif, France, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, Massachusetts General Hospital, Boston, MA, USA,